High platelet count and high probability of CALR detection in myeloproliferative neoplasms

Shirzad, Reza; Tahannejad, Zari; Mohamadi-asl, Javad; Seghatoleslami, Mohammad; Ahmadzadeh, Ahmad; Malehi, Amal Saki; Saki, Najmaldin

doi:10.1007/s00580-016-2343-9

Comp Clin Pathol

2016

DOI: 10.1007/s00580-016-2343-9

|View full text |Cite

High platelet count and high probability of CALR detection in myeloproliferative neoplasms

Reza Shirzad

Zari Tahannejad

Javad Mohamadi-asl

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…

9(5-bp insertion; c.1154_1155insTTGTC) in CALR were considered of pathologic significance. 5 There is considerable literature about risk factors, including smoking, obesity, diabetes, familial history, and etc. in the incidence trend of CVD development in younger patients.

…”

mentioning

confidence: 99%

Prevalence of Calreticulin exon 9 Mutation in Iranian Cardiovascular Patients

2021

Self Cite

View full text Add to dashboard Cite

Background: Calreticulin (CALR) is a 46 kDa protein in the endoplasmic reticulum and is one of the major proteins in ca2+ binding; it has a key role in oxidative stress, transcription factor activation, and as a chaperone in newly synthesized protein and glycoprotein folding. The high expression of CALR is pivotal for cardiac development in the embryonic period. It has been showed that mutation in exon 9 of CALR causes loss of C-terminal function and contributes to cardiovascular disease (CVD) development. Objective: It could conceivably be hypothesized that in addition to the general risk factors, the specific gene defects which are less considered can contribute to CVD development. In this regard in this study the possible existence of CALR mutations in CVD development is determine in patients younger than 40. Method: Thirty patients younger than 40 were recruited for this study, 86.7% (26) were male, and just 13.3% (4) were female. The amplification refractory mutation system-PCR was used to identified mutation in exon 9. The CVD risk factors, including blood pressure, type 2 diabetes, dyslipidemia, history of smoking, alcohol drinking, and familial CVD development were evaluated. Result: In none of the patients, CALR mutations were detected. Since CALR defect causes accumulation of glycogen in the heart's cells and contributes to CVD development, our results confirm this, so that 76.7% of patients did not have diabetes. Conclusion: The findings of the current study show there is no significant differences between exon 9 CALR mutation and CVD development.

show abstract

“…

…”

mentioning

confidence: 99%

Prevalence of Calreticulin exon 9 Mutation in Iranian Cardiovascular Patients

2021

Self Cite

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

High platelet count and high probability of CALR detection in myeloproliferative neoplasms

Cited by 1 publication

References 26 publications

Prevalence of Calreticulin exon 9 Mutation in Iranian Cardiovascular Patients

Prevalence of Calreticulin exon 9 Mutation in Iranian Cardiovascular Patients

Contact Info

Product

Resources

About